MedTrace Logo

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

NCT04644068 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 702

Last updated 2026-02-19

No results posted yet for this study

Summary

This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.

Conditions

Interventions

DRUG

AZD5305

Oral PARP inhibitor

DRUG

Paclitaxel

IV Anti-microtubule agent

DRUG

Carboplatin

IV Platinum chemotherapeutic

DRUG

T- Dxd

IV Antibody-drug conjugate

DRUG

Dato-DXd

IV Antibody-drug conjugate

DRUG

Camizestrant

Oral SERD Molecule

Sponsors & Collaborators

Principal Investigators

  • Timothy Yap · M.D. Anderson Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-12
Primary Completion
2027-05-28
Completion
2027-05-28
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Canada
  • China
  • Czechia
  • Hungary
  • Italy
  • Japan
  • Poland
  • Russia
  • South Korea
  • Spain
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04644068 on ClinicalTrials.gov